JP2024538755A5 - - Google Patents
Info
- Publication number
- JP2024538755A5 JP2024538755A5 JP2024521343A JP2024521343A JP2024538755A5 JP 2024538755 A5 JP2024538755 A5 JP 2024538755A5 JP 2024521343 A JP2024521343 A JP 2024521343A JP 2024521343 A JP2024521343 A JP 2024521343A JP 2024538755 A5 JP2024538755 A5 JP 2024538755A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- antibody
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253106P | 2021-10-06 | 2021-10-06 | |
| US63/253,106 | 2021-10-06 | ||
| US202163257901P | 2021-10-20 | 2021-10-20 | |
| US63/257,901 | 2021-10-20 | ||
| PCT/EP2022/077749 WO2023057535A1 (en) | 2021-10-06 | 2022-10-05 | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538755A JP2024538755A (ja) | 2024-10-23 |
| JP2024538755A5 true JP2024538755A5 (https=) | 2025-10-14 |
Family
ID=84286302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521343A Pending JP2024538755A (ja) | 2021-10-06 | 2022-10-05 | がんを処置するための、抗ｐｄ－１抗体との組合せにおけるｐｄ－ｌ１及びｃｄ１３７に対する多特異性結合剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240409653A1 (https=) |
| EP (1) | EP4412714A1 (https=) |
| JP (1) | JP2024538755A (https=) |
| KR (1) | KR20240082387A (https=) |
| CN (1) | CN119053340A (https=) |
| AU (1) | AU2022360108A1 (https=) |
| CA (1) | CA3233512A1 (https=) |
| IL (1) | IL311901A (https=) |
| MX (1) | MX2024004242A (https=) |
| WO (1) | WO2023057535A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025242827A1 (en) * | 2024-05-22 | 2025-11-27 | Genmab A/S | Bispecific antibody against pd-l1 and cd137 in combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| PT3514172T (pt) | 2014-04-01 | 2020-04-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Imunorrecetores específicos de claudina-6 e epítopos de células t |
| WO2017209053A1 (ja) | 2016-05-30 | 2017-12-07 | アステラス製薬株式会社 | 新規な遺伝子組換えワクシニアウイルス |
| US20190185571A1 (en) | 2016-07-28 | 2019-06-20 | Musc Foundation For Research Development | Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| CN120441704A (zh) * | 2019-06-26 | 2025-08-08 | 圆祥生技股份有限公司 | T细胞活化抗体 |
| EP4100059A1 (en) * | 2020-02-04 | 2022-12-14 | Genmab A/S | Antibodies for use in therapy |
| IL304295B2 (en) * | 2021-01-08 | 2025-07-01 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
-
2022
- 2022-10-05 CN CN202280079918.2A patent/CN119053340A/zh active Pending
- 2022-10-05 KR KR1020247014273A patent/KR20240082387A/ko active Pending
- 2022-10-05 JP JP2024521343A patent/JP2024538755A/ja active Pending
- 2022-10-05 IL IL311901A patent/IL311901A/en unknown
- 2022-10-05 CA CA3233512A patent/CA3233512A1/en active Pending
- 2022-10-05 US US18/698,354 patent/US20240409653A1/en active Pending
- 2022-10-05 EP EP22801732.3A patent/EP4412714A1/en active Pending
- 2022-10-05 AU AU2022360108A patent/AU2022360108A1/en active Pending
- 2022-10-05 MX MX2024004242A patent/MX2024004242A/es unknown
- 2022-10-05 WO PCT/EP2022/077749 patent/WO2023057535A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10058610B2 (en) | Methods for treating cancer by administering humanized pan-HER antibody compositions | |
| CN105636986B (zh) | 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物 | |
| JP2024525758A5 (https=) | ||
| US20220017617A1 (en) | Efficiently expressed egfr and pd-l1 bispecific binding proteins | |
| EP3929213A1 (en) | Anti-pd-l1 antibody and use thereof | |
| CN118201613A (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023519807A5 (https=) | ||
| JP2024536383A5 (https=) | ||
| JP2023551980A5 (https=) | ||
| JP2024538755A5 (https=) | ||
| JP2024523438A5 (https=) | ||
| CN119587691A (zh) | 抗her2抗体药物偶联物联合抗her2抗体治疗肿瘤 | |
| CN121358492A (zh) | 用于治疗多发性骨髓瘤的方法 | |
| JP2020508694A (ja) | ＥｒｂＢ２抗体およびその使用 | |
| EP4076538A1 (en) | Treatment with site specific her2 antibody-drug conjugates | |
| US20220259316A1 (en) | Multiple-Variable Dosage Regimen for the Treatment of Cancers with High Expression of EGFR | |
| US20220218838A1 (en) | Adc for a treatment concomitant with or subsequent to docetaxel | |
| EP4694894A1 (en) | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor | |
| WO2024263904A1 (en) | Methods for treatment of liver cancer | |
| JP2026506269A (ja) | 組換え抗体及びその用途 | |
| WO2026021442A1 (zh) | 抗体药物偶联物在制备治疗肺癌的药物中的用途 | |
| AU2024352029A1 (en) | Methods of reducing weight loss using anti-gdf15 antibodies | |
| WO2026077321A1 (zh) | 抗her2抗体药物偶联物和免疫检查点抑制剂的药物组合 | |
| WO2025242061A1 (zh) | 抗her2抗体药物偶联物治疗胆道癌的用途 | |
| CN121620371A (zh) | T细胞衔接蛋白在治疗癌症中的用途 |